GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cue Biopharma Inc (NAS:CUE) » Definitions » Net Debt Paydown Yield %

Cue Biopharma (Cue Biopharma) Net Debt Paydown Yield % : 4.79% (As of Jun. 07, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Cue Biopharma Net Debt Paydown Yield %?

Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt. As of today, Cue Biopharma's Net Debt Paydown Yield % was 4.79%.


Cue Biopharma Net Debt Paydown Yield % Historical Data

The historical data trend for Cue Biopharma's Net Debt Paydown Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cue Biopharma Net Debt Paydown Yield % Chart

Cue Biopharma Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Debt Paydown Yield %
Get a 7-Day Free Trial Premium Member Only -1.19 0.05 0.26 -11.04 2.20

Cue Biopharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Debt Paydown Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.31 -3.46 -0.70 2.20 4.18

Competitive Comparison of Cue Biopharma's Net Debt Paydown Yield %

For the Biotechnology subindustry, Cue Biopharma's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cue Biopharma's Net Debt Paydown Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cue Biopharma's Net Debt Paydown Yield % distribution charts can be found below:

* The bar in red indicates where Cue Biopharma's Net Debt Paydown Yield % falls into.



Cue Biopharma Net Debt Paydown Yield % Calculation

Cue Biopharma's Net Debt Paydown Yield % for the quarter that ended in Mar. 2024 is calculated as:

Net Debt Paydown Yield %
=( TTM Average Debt   (1-Year Ago))-TTM Average Debt )/Market Cap
=( 19.37-15.53 )/91.935837
=4.18 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.


Cue Biopharma  (NAS:CUE) Net Debt Paydown Yield % Explanation

Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.

In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.

We calculating the TTM average debt by adding up the total debt, calculated by the sum of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation, in the trailing twelve months(TTM) divided by the counts of the total debt, accoring to the company's report frequency.


Cue Biopharma Net Debt Paydown Yield % Related Terms

Thank you for viewing the detailed overview of Cue Biopharma's Net Debt Paydown Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cue Biopharma (Cue Biopharma) Business Description

Traded in Other Exchanges
Address
40 Guest Street, Boston, MA, USA, 02135
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its drug candidate comprises CUE-101, a variant form of the cytokine Interleukin-2 and a T cell antigen to target and activate T cells specific to HPV-related cancers. The other products under pipeline are CUE-102, CUE-103, CUE-400, and CUE-401.
Executives
Anish Suri officer: President and CSO 40 GUEST STREET, BOSTON MA 02135
Daniel R Passeri director, officer: CEO 40 GUEST STREET, BOSTON MA 02135
Pamela Garzone director C/O CUE BIOPHARMA, INC., 40 GUEST STREET, BOSTON MA 02135
Patrick Verheyen director C/O CUE BIOPHARMA, INC., 40 GUEST STREET, BOSTON MA 02135
Peter A Kiener director 40 GUEST STREET, BOSTON MA 02135
Matteo Levisetti officer: Chief Medical Officer C/O CUE BIOPHARMA, INC., 40 GUEST STREET, BOSTON MA 02135
Frank Morich director 40 GUEST STREET, BOSTON MA 02135
Fletcher Aaron G.l. director 40 GUEST STREET, BOSTON MA 02135
Patricia Nasshorn officer: Chief Business Officer C/O WOMEN FIRST HEALTHCARE INC, 12220 EL CAMINO REAL, SAN DIEGO CA 92130
Kerri-ann Millar officer: CFO 40 GUEST STREET, BOSTON MA 02135
Kenneth Pienta officer: Chief Medical Officer C/O CURIS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421
Sandercock Colin officer: SVP, General Counsel and Sec 40 GUEST STREET, BOSTON MA 02135
Tamar D Howson director
Barry J. Simon director 2533 SOUTH COAST HIGHWAY 101, SUITE 210, CARDIFF-BY-THE-SEA CA 92007
Frederick W Driscoll director

Cue Biopharma (Cue Biopharma) Headlines

From GuruFocus

Cue Biopharma Announces Chief Medical Officer Transition

By Stock market mentor Stock market mentor 01-23-2023

Cue Biopharma to Host Investor Call

By sperokesalga sperokesalga 06-07-2023

Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences

By Value_Insider Value_Insider 11-22-2022